Prostate Cancer, a new Decision Resources study, finds that prostate cancer (CaP) has recently emerged as a disease worthy of aggressive drug therapy. Clinicians now recognize that, in its aggressive form, CaP can affect relatively young and otherwise healthy men, significantly shortening their life span. Furthermore, chemotherapy agents have recently demonstrated positive results in CaP. These factors will drive substantial growth in sales of chemotherapy drugs and certain hormonal therapies.
New drug therapies, founded on knowledge about the biological mechanisms of tumor generation and spread, are poised to reinforce the role of chemotherapy. Key players evaluated in Prostate Cancer include the following:
Trastuzumab (Genentech/Roche's Herceptin) is undergoing Phase II trials in the United States to evaluate its potential in patients with recurrent or hormone-refractory prostate cancer.
Exisulind (Cell Pathways' Aptosyn) is an oral apoptosis modulator that selectively induces apoptosis in precancerous and cancerous cells while having minimal effects on normal cells. We anticipate that exisulind will prove beneficial in both metastatic and nonmetastatic locally advanced (stages III and IV) CaP.
Genta's Genasense (formerly G-3139), an antisense oligonucleotide designed to block production of Bcl-2 (a proto-oncogene), is currently the subject of a Phase II trial in the United States, where it is being evaluated in combination with docetaxel in patients with hormone-refractory prostate cancer whose tumors have not responded to previous chemotherapy.
Provenge (formerly APC-8015) is a dendritic-cell-based vaccine in Phase III development by Dendreon. In May 1999, Dendreon granted Kirin Brewery nonexclusive rights to its dendritic-cell therapy in Europe, Asia, and Oceania; in October 2000, Dendreon signed a collaboration agreement with the R.W. Johnson Pharmaceutical Research Institute. In January 2000, Provenge entered Phase III development to confirm earlier trial results, which suggest that the vaccine can delay the progression of CaP.
Prostate Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is a part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,